| Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib D Marin, A Bazeos, FX Mahon, L Eliasson, D Milojkovic, M Bua, ... Journal of clinical oncology 28 (14), 2381, 2010 | 1121 | 2010 |
| Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase … D Marin, AR Ibrahim, C Lucas, G Gerrard, L Wang, RM Szydlo, RE Clark, ... Journal of Clinical Oncology 30 (3), 232, 2012 | 590 | 2012 |
| Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy AR Ibrahim, L Eliasson, JF Apperley, D Milojkovic, M Bua, R Szydlo, ... Blood, The Journal of the American Society of Hematology 117 (14), 3733-3736, 2011 | 392 | 2011 |
| Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia D Milojkovic, E Nicholson, JF Apperley, TL Holyoake, P Shepherd, ... haematologica 95 (2), 224, 2010 | 157 | 2010 |
| Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies P Neelakantan, G Gerrard, C Lucas, D Milojkovic, P May, L Wang, ... Blood, The Journal of the American Society of Hematology 121 (14), 2739-2742, 2013 | 113 | 2013 |
| Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy AR Ibrahim, C Paliompeis, M Bua, D Milojkovic, R Szydlo, JS Khorashad, ... Blood, The Journal of the American Society of Hematology 116 (25), 5497-5500, 2010 | 81 | 2010 |
| EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors M Daghistani, D Marin, JS Khorashad, L Wang, PC May, C Paliompeis, ... Blood, The Journal of the American Society of Hematology 116 (26), 6014-6017, 2010 | 37 | 2010 |
| Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. A Bazeos, J Khorashad, FX Mahon, LL Eliasson, D Milojkovic, M Bua, ... Blood 114 (22), 3290, 2009 | 22 | 2009 |
| The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for ‘stopping’studies D Milojkovic, G Gerrard, C Paliompeis, M Bua, A Reid, M Alikian, ... Blood 118 (21), 605, 2011 | 13 | 2011 |
| Excellent outcome after repeated changes of tyrosine kinase inhibitor therapy for chronic myeloid leukaemia in complete cytogenetic response due to minor side effects. P Neelakantan, K Rezvani, P May, G Gerrard, B Marco, C Paliompeis, ... British journal of haematology 164 (4), 2014 | 6 | 2014 |
| Assessment of BCR-ABL1 Transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with imatinib D Milojkovic, AR Ibrahim, L Foroni, C Lucas, G Gerrard, L Wang, ... Blood 118 (21), 1680, 2011 | 6 | 2011 |
| Analysis of the Burden of Cytomegalovirus Infection and Disease in Hematopoietic Stem Cell Transplant Recipients S Monsalvo, S Lozano, D Avenoso, B Sevillano, P Woolley, N Farah, ... BONE MARROW TRANSPLANTATION 53, 539-540, 2018 | | 2018 |
| FOR PROOF ONLY AR Ibrahim, L Eliasson, JF Apperley, D Milojkovic, M Bua, R Szydlo, ... | | 2011 |
| Chronic Myeloid Leukemia-Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia D Milojkovic, E Nicholson, JF Apperley, TL Holyoake, P Shepherd, ... Haematologica 95 (2), 224, 2010 | | 2010 |
